{
    "clinical_study": {
        "@rank": "48509", 
        "arm_group": [
            {
                "arm_group_label": "VCIV - Modified manufacturing process (18-49 Years Old) Lot 1", 
                "arm_group_type": "Experimental", 
                "description": "Vero cell-derived trivalent influenza vaccine (VCIV)"
            }, 
            {
                "arm_group_label": "VCIV - Modified manufacturing process (18-49 Years Old) Lot 2", 
                "arm_group_type": "Experimental", 
                "description": "Vero cell-derived trivalent influenza vaccine (VCIV)"
            }, 
            {
                "arm_group_label": "VCIV - Modified manufacturing process (18-49 Years Old) Lot 3", 
                "arm_group_type": "Experimental", 
                "description": "Vero cell-derived trivalent influenza vaccine (VCIV)"
            }, 
            {
                "arm_group_label": "VCIV manufactured with current process (18-49 Years Old)", 
                "arm_group_type": "Active Comparator", 
                "description": "Vero cell-derived trivalent influenza vaccine (VCIV)"
            }, 
            {
                "arm_group_label": "Fluzone\u00ae (18-49 Years Old)", 
                "arm_group_type": "Active Comparator", 
                "description": "Fluzone\u00ae, licensed trivalent influenza vaccine (TIV)"
            }, 
            {
                "arm_group_label": "VCIV - Modified manufacturing process (\u226550 Years Old) Lot 1", 
                "arm_group_type": "Experimental", 
                "description": "Vero cell-derived trivalent influenza vaccine (VCIV)"
            }, 
            {
                "arm_group_label": "VCIV - Modified manufacturing process (\u226550 Years Old) Lot 2", 
                "arm_group_type": "Experimental", 
                "description": "Vero cell-derived trivalent influenza vaccine (VCIV)"
            }, 
            {
                "arm_group_label": "VCIV - Modified manufacturing process (\u226550 Years Old) Lot 3", 
                "arm_group_type": "Experimental", 
                "description": "Vero cell-derived trivalent influenza vaccine (VCIV)"
            }, 
            {
                "arm_group_label": "Fluzone\u00ae (\u226550 Years Old)", 
                "arm_group_type": "Active Comparator", 
                "description": "Fluzone\u00ae, licensed trivalent influenza vaccine (TIV)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if a Vero cell-derived trivalent seasonal\n      influenza vaccine produced by the modified manufacturing process:\n\n        1. induces immune responses comparable to that produced by the current manufacturing\n           process\n\n        2. has an acceptable safety profile compared to a licensed trivalent seasonal influenza\n           vaccine\n\n        3. demonstrates consistency of immune response among three different lots."
        }, 
        "brief_title": "Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participant is 18 to 49 years of age, inclusive, at the time of screening (for Cohort\n             18 to 49 years of age);\n\n          -  Participant is 50 years of age, inclusive, or older at the time of screening (for\n             Cohort 50 years of age or older);\n\n          -  Participant gave written informed consent prior to study entry\n\n          -  Participant is generally healthy without any significant medical risk conditions, as\n             determined by the Investigator's clinical judgment through collection of medical\n             history and performance of a physical examination;\n\n          -  Participant is willing and able to comply with the requirements of the protocol;\n\n          -  Participant agrees to keep a record of symptoms for the duration of the study;\n\n          -  If female and capable of bearing children - participant has a negative urine\n             pregnancy test at the study site, within 36 hours prior to vaccination, and agrees to\n             employ adequate birth control measures for the duration of the study. For the\n             purposes of this study adequate birth control measures incorporate one of the\n             following FDA approved birth control measures for the duration of the study:\n\n               -  Hormonal types of birth control (such as implants, birth control pills, patches\n                  or other methods) or an intrauterine device, OR\n\n               -  A barrier type of birth control measure (i.e., condoms, diaphragms, cervical\n                  caps, etc.).\n\n        Exclusion Criteria:\n\n          -  Participant has been vaccinated with seasonal trivalent influenza vaccine in the\n             current season;\n\n          -  Participant has an oral temperature of \u2265100.4\u00b0F (\u226538.0\u00b0C) on the day of vaccination\n             in this study;\n\n          -  Participant has received a live vaccine within 4 weeks, or an inactivated or subunit\n             vaccine within 2 weeks of study entry;\n\n          -  Participant with a known history of infection with Human Immunodeficiency Virus\n             (HIV), Hepatitis B Virus (HBsAgs) or Hepatitis C Virus (HCV);\n\n          -  Participant has any medically diagnosed or suspected immune deficient condition based\n             on medical history and physical examination as determined by the Investigator;\n\n          -  Participant has an immune compromising condition or disease, or is currently\n             undergoing a form of treatment or was undergoing a form of treatment within 30 days\n             prior to study entry that can be expected to influence immune response. Such\n             treatment includes, but is not limited to, systemic or high dose inhaled\n             corticosteroids (> 800 \u03bcg/day of beclomethasone dipropionate or equivalent),\n             radiation treatment or other immunosuppressive or cytotoxic drugs (use of inhaled and\n             nasal steroids will be permitted);\n\n          -  Participant has a known history of Guillain Barr\u00e9 Syndrome, demyelinating disorders\n             (including acute demyelinating encephalomyelitis (ADEM), Multiple Sclerosis) or\n             convulsions;\n\n          -  Participant has a history of severe allergic reactions or anaphylaxis as determined\n             by the Investigator;\n\n          -  Participant has a rash, dermatologic condition or tattoos which may interfere with\n             injection site reaction rating as determined by the Investigator;\n\n          -  Participant has received any blood products (e.g. blood transfusion or\n             immunoglobulins) within 90 days prior to study entry;\n\n          -  Participant has donated one or more units of blood (approximately 450 mL) or plasma\n             within 30 days prior to study entry;\n\n          -  Participant has a functional or surgical asplenia;\n\n          -  Participant has a known or suspected problem with alcohol or drug abuse as determined\n             by the Investigator;\n\n          -  Participant is a member of the team conducting this study or is in a dependent\n             relationship with one of the study team members. Dependent relationships include\n             close relatives (ie., children, partner/spouse, siblings, parents) as well as\n             employees of the Investigator or study site personnel conducting the study;\n\n          -  If female, participant is pregnant or lactating at the time of study enrollment;\n\n          -  Participant is currently enrolled or has participated in another clinical study\n             involving an investigational product (IP) or investigational device within 30 days\n             prior to study enrolment or is scheduled to participate in another clinical study\n             involving an IP or investigational device during the course of this study;\n\n          -  Participant has any condition that in the opinion of the Investigator would interfere\n             with evaluation of the vaccine or interpretation of study results."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1929", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01773928", 
            "org_study_id": "721104"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "VCIV - Modified manufacturing process (18-49 Years Old) Lot 1", 
                    "VCIV - Modified manufacturing process (18-49 Years Old) Lot 2", 
                    "VCIV - Modified manufacturing process (18-49 Years Old) Lot 3", 
                    "VCIV - Modified manufacturing process (\u226550 Years Old) Lot 1", 
                    "VCIV - Modified manufacturing process (\u226550 Years Old) Lot 2", 
                    "VCIV - Modified manufacturing process (\u226550 Years Old) Lot 3"
                ], 
                "intervention_name": "Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "VCIV manufactured with current process (18-49 Years Old)", 
                "intervention_name": "VCIV manufactured with the current manufacturing process (VCIV current)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Fluzone\u00ae (18-49 Years Old)", 
                    "Fluzone\u00ae (\u226550 Years Old)"
                ], 
                "intervention_name": "Fluzone\u00ae, licensed trivalent influenza vaccine (TIV)", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Active immunization against influenza disease", 
        "lastchanged_date": "April 16, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chandler", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85224"
                    }, 
                    "name": "East Valley Family Physicians, PLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103"
                    }, 
                    "name": "California Research Foundation"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94102"
                    }, 
                    "name": "Benchmark Research San Francisco"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coral Gables", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33134"
                    }, 
                    "name": "Clinical Research of South Florida"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockbridge", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30281"
                    }, 
                    "name": "Clinical Research Atlanta"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wichita", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "67207"
                    }, 
                    "name": "Heartland Research Associates, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64114"
                    }, 
                    "name": "The Center for Pharmaceutical Research, P.C."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63141"
                    }, 
                    "name": "Sundance Clinical Research, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14609"
                    }, 
                    "name": "Rochester Clinical Research Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cary", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27518"
                    }, 
                    "name": "PMG Research of Cary, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44122"
                    }, 
                    "name": "Rapid Medical Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spartanburg", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29303"
                    }, 
                    "name": "Spartanburg Medical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78705"
                    }, 
                    "name": "Benchmark Research Austin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76135"
                    }, 
                    "name": "Benchmark Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84124"
                    }, 
                    "name": "Jean Brown Research"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "9", 
        "official_title": "Randomized, Age-stratified, Double Blind, Controlled Phase 3 Study Comparing a Vero Cell-derived Trivalent Seasonal Influenza Vaccine Made by the Modified Manufacturing Process With Vaccine Made by the Current Manufacturing Process and a Licensed Trivalent Influenza Vaccine in Healthy Adults Aged 18 Years and Older", 
        "overall_official": {
            "affiliation": "Baxter Healthcare Corporation", 
            "last_name": "Nirjhar Chatterjee, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Hemagglutination inhibition antibody (HIA) titer for each of the three antigens contained in the vaccine", 
                "safety_issue": "No", 
                "time_frame": "21 days post-vaccination"
            }, 
            {
                "measure": "Number of participants with fever", 
                "safety_issue": "Yes", 
                "time_frame": "onset within 7 days post vaccination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01773928"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of participants with seroprotective antibody titer [reciprocal HIA titer \u226540] for each of the three antigens contained in the vaccine", 
                "safety_issue": "No", 
                "time_frame": "21 days post-vaccination"
            }, 
            {
                "description": "Seroconversion is defined as a \u2265 4-fold increase in HIA titer from baseline OR a reciprocal HIA titer \u2265 40 when there is no detectable HIA titer (reciprocal HIA titer < 10) at baseline", 
                "measure": "Number of participants demonstrating seroconversion to each of the three antigens contained in the vaccine", 
                "safety_issue": "No", 
                "time_frame": "21 days post-vaccination"
            }, 
            {
                "measure": "Fold increase of HIA titer for each of the three antigens contained in the vaccine as compared to baseline", 
                "safety_issue": "No", 
                "time_frame": "21 days post-vaccination"
            }, 
            {
                "measure": "Number of participants with solicited systemic reactions", 
                "safety_issue": "Yes", 
                "time_frame": "within 7 days post-vaccination"
            }, 
            {
                "measure": "Number of participants with injection site reactions", 
                "safety_issue": "Yes", 
                "time_frame": "within 7 days post-vaccination"
            }, 
            {
                "measure": "Frequency and severity of each solicited systemic reaction and injection site reaction", 
                "safety_issue": "Yes", 
                "time_frame": "within 7 days of vaccination"
            }, 
            {
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "within 21 days post-vaccination"
            }, 
            {
                "measure": "Frequency and severity of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "within 21 days post-vaccination"
            }
        ], 
        "source": "Baxter Healthcare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Baxter Healthcare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}